英国心血管学会与缺血性心脏病临床研究:从RITA到ORBITA及未来
本文以历史视角回顾英国心血管学会(BCS)在缺血性心脏病(IHD)临床试验中的影响,涵盖稳定IHD和急性冠脉综合征的诊断、治疗与管理研究。文章讨论BCS支持原始RITA试验的角色,并强调心绞痛管理的变化,提供关于微血管病、非阻塞性冠脉缺血症状及非阻塞性冠脉心肌梗死的当代与未来见解。
要点
- BCS通过支持RITA等试验推动了缺血性心脏病介入策略的证据积累。
- 心绞痛管理理念更新,关注微血管病和非阻塞性冠脉疾病。
- 未来研究需整合患者与公众参与及多方利益相关者协作。
核心结论
- BCS在缺血性心脏病临床试验历史中发挥关键作用,并持续关注心绞痛管理的新兴领域。
研究设计与样本
- 本文为历史回顾与观点文章,覆盖稳定IHD和急性冠脉综合征的临床试验,包括诊断、治疗和管理干预。
主要发现
- BCS支持了原始RITA试验,并推动心绞痛管理理念向微血管病和非阻塞性冠脉疾病演变。
临床怎么用
- 临床应关注非阻塞性冠脉疾病导致的心肌缺血和心肌梗死,并重视患者与公众参与研究。
局限性
- 本文为简要概述,未提供系统检索或定量数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In this article, we provide a historical view of key aspects of British Cardiovascular Society (BCS) influence in clinical trials of ischaemic heart disease (IHD) followed by key research and developments, notable publications and future perspectives. We discuss the role of the BCS and its members. The scope of this article covers clinical trials in stable IHD and acute coronary syndromes, including interventions relating to diagnosis, treatment and management. We discuss the role of the BCS in supporting the original RITA trials. We highlight the changing face of angina and its management providing contemporary and future insights into microvascular disease, ischaemic symptoms with no obstructive coronary arteries and, relatedly, myocardial infarction with no obstructive coronary arteries. The article is presented as a brief overview of the BCS in IHD research, relationships with stakeholders, patient and public involvement and clinical trials from the perspective of past, present and future possibilities.
引用
- Al-Lamee R, Aubiniere-Robb L, Berry C, et al. The British Cardiovascular Society and clinical studies in ischaemic heart disease: from RITA to ORBITA, and beyond. Heart. 2022. PMID: 35459731. doi:10.1136/heartjnl-2021-320150
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。